Safety and Outcomes of Oral Graded Challenges to Amoxicillin without Prior Skin Testing

Melissa M. Iammatteo, Santiago Alvarez Arango, Denisa E. Ferastraoaru, Nadeem A. Akbar, Andrew Y. Lee, Hillel W. Cohen, Elina Jerschow

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: Unconfirmed penicillin allergy poses substantial public health consequences. The most widely accepted protocol to evaluate penicillin allergy is skin testing followed by an amoxicillin challenge. Objective: To evaluate the safety of direct oral graded challenges to amoxicillin. Methods: A prospective single-blind clinical trial with historical controls of patients ≥7 years old with historical non–life-threatening reactions to penicillin was conducted. Patients received placebo followed by a 2-step graded challenge to amoxicillin. The allergic reaction rate was compared with the rate observed in our previous study that included skin testing and with the currently reported penicillin allergy prevalence in the US population. Results: Of the 155 participants who completed an amoxicillin challenge, 120 patients (77.4%) experienced no reaction whereas 31 patients (20%) experienced nonallergic reactions to either placebo (n = 16) or amoxicillin (n = 15). Four patients (2.6%) developed mild allergic reactions. Significantly (P =.03) fewer patients (4 of 155, 2.6%, 95% confidence interval [CI]: 1.0%, 6.5%) were determined to be allergic compared with 14 of 170 subjects (8.2%, 95% CI: 5.0%, 13.4%) in our previous study where patients were determined to be allergic based on either positive skin tests (n = 11) or allergic challenge reactions after negative skin tests (n = 3). This 2.6% reaction rate was also significantly less than the 10% reported US prevalence of penicillin allergy (P =.003). Conclusions: Placebo-controlled oral graded challenges to amoxicillin without prior skin testing may be safe for patients ≥7 years old with non–life-threatening historical reactions to penicillin. Amoxicillin can be tolerated by the majority of patients with self-reported penicillin allergy.

Original languageEnglish (US)
JournalJournal of Allergy and Clinical Immunology: In Practice
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Amoxicillin
Penicillins
Hypersensitivity
Safety
Skin
Placebos
Skin Tests
Confidence Intervals
Public Health
Clinical Trials

Keywords

  • Adverse drug reaction
  • Drug provocation test
  • Graded challenge
  • Hypersensitivity reaction
  • Penicillin allergy
  • Placebo

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Safety and Outcomes of Oral Graded Challenges to Amoxicillin without Prior Skin Testing. / Iammatteo, Melissa M.; Alvarez Arango, Santiago; Ferastraoaru, Denisa E.; Akbar, Nadeem A.; Lee, Andrew Y.; Cohen, Hillel W.; Jerschow, Elina.

In: Journal of Allergy and Clinical Immunology: In Practice, 01.01.2018.

Research output: Contribution to journalArticle

@article{eca13de52d1c4b388cf6b61dae9134c8,
title = "Safety and Outcomes of Oral Graded Challenges to Amoxicillin without Prior Skin Testing",
abstract = "Background: Unconfirmed penicillin allergy poses substantial public health consequences. The most widely accepted protocol to evaluate penicillin allergy is skin testing followed by an amoxicillin challenge. Objective: To evaluate the safety of direct oral graded challenges to amoxicillin. Methods: A prospective single-blind clinical trial with historical controls of patients ≥7 years old with historical non–life-threatening reactions to penicillin was conducted. Patients received placebo followed by a 2-step graded challenge to amoxicillin. The allergic reaction rate was compared with the rate observed in our previous study that included skin testing and with the currently reported penicillin allergy prevalence in the US population. Results: Of the 155 participants who completed an amoxicillin challenge, 120 patients (77.4{\%}) experienced no reaction whereas 31 patients (20{\%}) experienced nonallergic reactions to either placebo (n = 16) or amoxicillin (n = 15). Four patients (2.6{\%}) developed mild allergic reactions. Significantly (P =.03) fewer patients (4 of 155, 2.6{\%}, 95{\%} confidence interval [CI]: 1.0{\%}, 6.5{\%}) were determined to be allergic compared with 14 of 170 subjects (8.2{\%}, 95{\%} CI: 5.0{\%}, 13.4{\%}) in our previous study where patients were determined to be allergic based on either positive skin tests (n = 11) or allergic challenge reactions after negative skin tests (n = 3). This 2.6{\%} reaction rate was also significantly less than the 10{\%} reported US prevalence of penicillin allergy (P =.003). Conclusions: Placebo-controlled oral graded challenges to amoxicillin without prior skin testing may be safe for patients ≥7 years old with non–life-threatening historical reactions to penicillin. Amoxicillin can be tolerated by the majority of patients with self-reported penicillin allergy.",
keywords = "Adverse drug reaction, Drug provocation test, Graded challenge, Hypersensitivity reaction, Penicillin allergy, Placebo",
author = "Iammatteo, {Melissa M.} and {Alvarez Arango}, Santiago and Ferastraoaru, {Denisa E.} and Akbar, {Nadeem A.} and Lee, {Andrew Y.} and Cohen, {Hillel W.} and Elina Jerschow",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.jaip.2018.05.008",
language = "English (US)",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "Elsevier",

}

TY - JOUR

T1 - Safety and Outcomes of Oral Graded Challenges to Amoxicillin without Prior Skin Testing

AU - Iammatteo, Melissa M.

AU - Alvarez Arango, Santiago

AU - Ferastraoaru, Denisa E.

AU - Akbar, Nadeem A.

AU - Lee, Andrew Y.

AU - Cohen, Hillel W.

AU - Jerschow, Elina

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Unconfirmed penicillin allergy poses substantial public health consequences. The most widely accepted protocol to evaluate penicillin allergy is skin testing followed by an amoxicillin challenge. Objective: To evaluate the safety of direct oral graded challenges to amoxicillin. Methods: A prospective single-blind clinical trial with historical controls of patients ≥7 years old with historical non–life-threatening reactions to penicillin was conducted. Patients received placebo followed by a 2-step graded challenge to amoxicillin. The allergic reaction rate was compared with the rate observed in our previous study that included skin testing and with the currently reported penicillin allergy prevalence in the US population. Results: Of the 155 participants who completed an amoxicillin challenge, 120 patients (77.4%) experienced no reaction whereas 31 patients (20%) experienced nonallergic reactions to either placebo (n = 16) or amoxicillin (n = 15). Four patients (2.6%) developed mild allergic reactions. Significantly (P =.03) fewer patients (4 of 155, 2.6%, 95% confidence interval [CI]: 1.0%, 6.5%) were determined to be allergic compared with 14 of 170 subjects (8.2%, 95% CI: 5.0%, 13.4%) in our previous study where patients were determined to be allergic based on either positive skin tests (n = 11) or allergic challenge reactions after negative skin tests (n = 3). This 2.6% reaction rate was also significantly less than the 10% reported US prevalence of penicillin allergy (P =.003). Conclusions: Placebo-controlled oral graded challenges to amoxicillin without prior skin testing may be safe for patients ≥7 years old with non–life-threatening historical reactions to penicillin. Amoxicillin can be tolerated by the majority of patients with self-reported penicillin allergy.

AB - Background: Unconfirmed penicillin allergy poses substantial public health consequences. The most widely accepted protocol to evaluate penicillin allergy is skin testing followed by an amoxicillin challenge. Objective: To evaluate the safety of direct oral graded challenges to amoxicillin. Methods: A prospective single-blind clinical trial with historical controls of patients ≥7 years old with historical non–life-threatening reactions to penicillin was conducted. Patients received placebo followed by a 2-step graded challenge to amoxicillin. The allergic reaction rate was compared with the rate observed in our previous study that included skin testing and with the currently reported penicillin allergy prevalence in the US population. Results: Of the 155 participants who completed an amoxicillin challenge, 120 patients (77.4%) experienced no reaction whereas 31 patients (20%) experienced nonallergic reactions to either placebo (n = 16) or amoxicillin (n = 15). Four patients (2.6%) developed mild allergic reactions. Significantly (P =.03) fewer patients (4 of 155, 2.6%, 95% confidence interval [CI]: 1.0%, 6.5%) were determined to be allergic compared with 14 of 170 subjects (8.2%, 95% CI: 5.0%, 13.4%) in our previous study where patients were determined to be allergic based on either positive skin tests (n = 11) or allergic challenge reactions after negative skin tests (n = 3). This 2.6% reaction rate was also significantly less than the 10% reported US prevalence of penicillin allergy (P =.003). Conclusions: Placebo-controlled oral graded challenges to amoxicillin without prior skin testing may be safe for patients ≥7 years old with non–life-threatening historical reactions to penicillin. Amoxicillin can be tolerated by the majority of patients with self-reported penicillin allergy.

KW - Adverse drug reaction

KW - Drug provocation test

KW - Graded challenge

KW - Hypersensitivity reaction

KW - Penicillin allergy

KW - Placebo

UR - http://www.scopus.com/inward/record.url?scp=85048994071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048994071&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2018.05.008

DO - 10.1016/j.jaip.2018.05.008

M3 - Article

C2 - 29802906

AN - SCOPUS:85048994071

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

SN - 2213-2198

ER -